Sophiris Bio (OTCMKTS:SPHS) & Prestige Consumer Healthcare (NYSE:PBH) Financial Review

Sophiris Bio (OTCMKTS:SPHSGet Rating) and Prestige Consumer Healthcare (NYSE:PBHGet Rating) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.

Valuation and Earnings

This table compares Sophiris Bio and Prestige Consumer Healthcare’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sophiris Bio N/A N/A N/A N/A N/A
Prestige Consumer Healthcare $1.09 billion 3.04 $205.38 million $4.12 16.19

Prestige Consumer Healthcare has higher revenue and earnings than Sophiris Bio.

Profitability

This table compares Sophiris Bio and Prestige Consumer Healthcare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sophiris Bio N/A N/A N/A
Prestige Consumer Healthcare 18.83% 12.88% 5.52%

Insider & Institutional Ownership

100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 4.5% of Sophiris Bio shares are held by insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Sophiris Bio and Prestige Consumer Healthcare, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sophiris Bio 0 0 0 0 N/A
Prestige Consumer Healthcare 0 1 4 0 2.80

Prestige Consumer Healthcare has a consensus price target of $71.00, indicating a potential upside of 6.41%.

Risk & Volatility

Sophiris Bio has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Summary

Prestige Consumer Healthcare beats Sophiris Bio on 6 of the 8 factors compared between the two stocks.

About Sophiris Bio

(Get Rating)

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.

About Prestige Consumer Healthcare

(Get Rating)

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.